Abstract
High-risk neuroblastoma continues to have a poor prognosis, stimulating the ongoing development of alternative immune-therapy approaches. Despite exciting preclinical results, clinical outcomes have been less clear. Recently we identified that neuroblastoma expresses Arginase II, depleting local and systemic arginine concentrations, and suppression of autologous and engineered T cell immunity.